FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4211074038> ?p ?o ?g. }

• W4211074038 abstract "Interferons (IFNs)-beta and glatiramer acetate (GA) were the first two disease-modifying therapies (DMTs) approved 15 years ago for the treatment of multiple sclerosis (MS). DMTs prescription rates as first or switching therapies and their costs have increased substantially over the past decade. As more DMTs become available, the choice of a specific DMT should reflect the risk/benefit profile, as well as the impact on quality profile. As MS cohorts enrolled in different studies can vary significantly, head-to-head trials are considered the best approach for gaining objective reliable data when two different drugs are compared. The purpose of this study is to summarise available evidence on the comparative effectiveness of IFNs-beta and GA on disease course through a systematic review of head-to-head trials.To assess whether IFNs-beta and GA differ in terms of safety and efficacy in the treatment of patients with relapsing-remitting MS (RRMS).We searched the Trials Specialised Register of the Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group (29 October 2013) and the reference lists of retrieved articles. We contacted trialists and pharmaceutical companies.Randomised controlled trials (RCTs) comparing directly IFNs-beta versus GA in study participants affected by RRMS.We used standard methodological procedures as expected by The Cochrane Collaboration.Five trials contributed to this review. A total of 2858 participants were randomly assigned to IFNs (1679) and GA (1179). The treatment duration was three years for one study and two years for the other four RCTs. The IFNs analysed in comparison with GA were IFN-beta 1b 250 mcg (two trials, 933 participants), IFN-beta 1a 44 mcg (two trials, 441 participants) and IFN-beta 1a 30 mcg (two trials, 305 participants). Enrolled participants were affected by active RRMS. All studies were at high risk for attrition bias.Both therapies showed similar clinical efficacy at 24 months, given the primary outcome variables (number of participants with relapse (risk ratio (RR) 1.04, 95% confidence interval (CI) 0.87 to 1.24) or progression (RR 1.11, 95% CI 0.91 to 1.35)). However at 36 months, evidence from a single study suggests that relapse rates were higher in the group given IFNs than in the GA group (RR 1.40, 95% CI 1.13 to 1.7, P value 0.002).Secondary magnetic resonance imaging (MRI) outcomes analysis showed that effects on new or enlarging T2- or gadolinium (Gd)-enhancing lesions at 24 months were similar (mean difference (MD) -0.01, 95% CI -0.28 to 0.26, and MD -0.14, 95% CI -0.30 to 0.02, respectively). However, the reduction in T2- and T1-weighted lesion volume was significantly greater in the groups given IFNs than in the GA groups (MD -0.58, 95% CI -0.99 to -0.18, P value 0.004, and MD -0.20, 95% CI -0.33 to -0.07, P value 0.003, respectively).The number of participants who dropped out of the study because of adverse events was similar in the two groups (RR 0.95, 95% CI 0.64 to 1.40).The quality of evidence for primary outcomes was judged as moderate for clinical end points, but for safety and some MRI outcomes (number of active T2 lesions), quality was judged as low.The effects of IFNs-beta and GA in the treatment of patients with RRMS, including clinical (e.g. patients with relapse, risk to progression) and MRI (Gd-enhancing lesions) activity measures, seem to be similar or to show only small differences. When MRI lesion load accrual is considered, the effect of the two treatments differs, in that IFNs-beta were found to limit the increase in lesion burden as compared with GA. Evidence was insufficient for a comparison of the effects of the two treatments on patient-reported outcomes, such as quality of life measures." @default.
• W4211074038 created "2022-02-13" @default.
• W4211074038 creator A5000607550 @default.
• W4211074038 creator A5013675218 @default.
• W4211074038 creator A5016355439 @default.
• W4211074038 creator A5030382754 @default.
• W4211074038 creator A5057071067 @default.
• W4211074038 creator A5059578809 @default.
• W4211074038 creator A5064052926 @default.
• W4211074038 creator A5073696325 @default.
• W4211074038 creator A5075596287 @default.
• W4211074038 creator A5080439497 @default.
• W4211074038 date "2014-07-26" @default.
• W4211074038 modified "2023-10-17" @default.
• W4211074038 title "Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis" @default.
• W4211074038 cites W1247968195 @default.
• W4211074038 cites W1512495229 @default.
• W4211074038 cites W1545382406 @default.
• W4211074038 cites W1580917658 @default.
• W4211074038 cites W1943094391 @default.
• W4211074038 cites W1964134050 @default.
• W4211074038 cites W1966953116 @default.
• W4211074038 cites W1973550674 @default.
• W4211074038 cites W1975104912 @default.
• W4211074038 cites W1977938504 @default.
• W4211074038 cites W1988037885 @default.
• W4211074038 cites W1990918979 @default.
• W4211074038 cites W1998609863 @default.
• W4211074038 cites W2005506388 @default.
• W4211074038 cites W2013370381 @default.
• W4211074038 cites W2015684075 @default.
• W4211074038 cites W2022697992 @default.
• W4211074038 cites W2029064702 @default.
• W4211074038 cites W2034685098 @default.
• W4211074038 cites W2050002044 @default.
• W4211074038 cites W2053898472 @default.
• W4211074038 cites W2059145443 @default.
• W4211074038 cites W2059349666 @default.
• W4211074038 cites W2060143655 @default.
• W4211074038 cites W2061789642 @default.
• W4211074038 cites W2067750315 @default.
• W4211074038 cites W2076290890 @default.
• W4211074038 cites W2082461176 @default.
• W4211074038 cites W2083061008 @default.
• W4211074038 cites W2094463347 @default.
• W4211074038 cites W2100157528 @default.
• W4211074038 cites W2105490558 @default.
• W4211074038 cites W2107328434 @default.
• W4211074038 cites W2112165124 @default.
• W4211074038 cites W2114049340 @default.
• W4211074038 cites W2115989506 @default.
• W4211074038 cites W2122545833 @default.
• W4211074038 cites W2124720965 @default.
• W4211074038 cites W2125435699 @default.
• W4211074038 cites W2130355701 @default.
• W4211074038 cites W2131420603 @default.
• W4211074038 cites W2138393161 @default.
• W4211074038 cites W2139367012 @default.
• W4211074038 cites W2141919552 @default.
• W4211074038 cites W2143205494 @default.
• W4211074038 cites W2159871048 @default.
• W4211074038 cites W2162791471 @default.
• W4211074038 cites W2164331547 @default.
• W4211074038 cites W2164832046 @default.
• W4211074038 cites W2166983650 @default.
• W4211074038 cites W2171084233 @default.
• W4211074038 cites W2314350016 @default.
• W4211074038 cites W2916040650 @default.
• W4211074038 cites W4211254511 @default.
• W4211074038 cites W4366064463 @default.
• W4211074038 doi "https://doi.org/10.1002/14651858.cd009333.pub2" @default.
• W4211074038 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25062935" @default.
• W4211074038 hasPublicationYear "2014" @default.
• W4211074038 type Work @default.
• W4211074038 citedByCount "17" @default.
• W4211074038 countsByYear W42110740382015 @default.
• W4211074038 countsByYear W42110740382016 @default.
• W4211074038 countsByYear W42110740382017 @default.
• W4211074038 countsByYear W42110740382018 @default.
• W4211074038 countsByYear W42110740382019 @default.
• W4211074038 countsByYear W42110740382022 @default.
• W4211074038 crossrefType "reference-entry" @default.
• W4211074038 hasAuthorship W4211074038A5000607550 @default.
• W4211074038 hasAuthorship W4211074038A5013675218 @default.
• W4211074038 hasAuthorship W4211074038A5016355439 @default.
• W4211074038 hasAuthorship W4211074038A5030382754 @default.
• W4211074038 hasAuthorship W4211074038A5057071067 @default.
• W4211074038 hasAuthorship W4211074038A5059578809 @default.
• W4211074038 hasAuthorship W4211074038A5064052926 @default.
• W4211074038 hasAuthorship W4211074038A5073696325 @default.
• W4211074038 hasAuthorship W4211074038A5075596287 @default.
• W4211074038 hasAuthorship W4211074038A5080439497 @default.
• W4211074038 hasConcept C126322002 @default.
• W4211074038 hasConcept C168563851 @default.
• W4211074038 hasConcept C17744445 @default.
• W4211074038 hasConcept C1862650 @default.
• W4211074038 hasConcept C189708586 @default.
• W4211074038 hasConcept C197934379 @default.
• W4211074038 hasConcept C199539241 @default.
• W4211074038 hasConcept C203014093 @default.

• next